Rimegepant
Migraine With Aura
University of South FloridaSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 89/ 100
Competitive context
21 Active assets in the Migraine With Aura cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topamax Tongji Hospital | Phase 4 | BBB |
Dihydroergotamine mesylate Satsuma Pharmaceuticals, Inc. | Phase 3 | BB |
PROPRANOLOL Norwegian University of Science and Technology | Phase 3 | BB |
ALMOTRIPTAN Messoud Ashina, MD | Phase 4 | BB |
Treximet® University of Aarhus | Phase 3 | BB |
View all 49 →
Same molecule, other indications
Rimegepant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →